Related Experiment Videos
Cancer vaccines: challenges and potential solutions
K E Hellström1, P Gladstone, I Hellström
1Bristol-Myers Squibb Pharmacetuical Research Institute, Seattle, WA 98121, USA.
Abstract:
Almost a century has passed since immunotherapy of cancer was first attempted using cancer immunogens (vaccines); however, its clinical impact remains modest. Although initial concerns about a lack of human tumor antigens have decreased, prevailing issues include inefficient procedures for immunization and downregulated expression of major histocompatibility complex (MHC) class I molecules in tumor cells. While immunization can be improved, deficient MHC class I expression remains a problem, because it hampers the ability of tumor cells to present antigens for killing by CD8+ T cells. These are the major mediators of tumor destruction, and they have little or no activity against antigen-negative bystander cells. However, there are reasons to be optimistic that therapeutic vaccination against cancer antigens might become a reality at last.
Insights
Cancer immunotherapy using vaccines has shown modest clinical impact due to poor immunization and reduced major histocompatibility complex (MHC) class I expression on tumors. Optimizing these factors offers hope for effective cancer antigen vaccination.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Cancer immunotherapy using vaccines has been attempted for nearly a century with limited success.
- Key challenges include inefficient immunization protocols and reduced expression of major histocompatibility complex (MHC) class I molecules on tumor cells.
- Deficient MHC class I expression hinders antigen presentation to CD8+ T cells, crucial for tumor cell destruction.
Purpose of the Study:
- To review the historical context and current challenges in cancer vaccine immunotherapy.
- To discuss the significance of MHC class I expression in anti-tumor immune responses.
- To explore reasons for optimism regarding the future of therapeutic cancer vaccination.
Main Methods:
- Review of existing literature on cancer immunotherapy and tumor immunology.
- Analysis of the role of MHC class I molecules in T cell-mediated tumor surveillance.
- Discussion of strategies to improve immunization and overcome immune evasion mechanisms.
Main Results:
- Despite advancements, clinical impact of cancer vaccines remains modest.
- Downregulated MHC class I expression is a significant barrier to effective T cell-mediated tumor killing.
- CD8+ T cells, the primary mediators of tumor destruction, are ineffective against antigen-negative tumor cells.
Conclusions:
- Improving immunization procedures is necessary but insufficient to overcome current limitations.
- Addressing deficient MHC class I expression is critical for successful therapeutic cancer vaccination.
- Despite challenges, advancements suggest therapeutic cancer antigen vaccination may become a clinical reality.